Journal of Clinical Pediatrics >
Renal pathologic classification and treatment strategy in children with lupus nephritis
Received date: 2023-09-18
Online published: 2023-12-04
Lupus nephritis (LN) is the most common glomerular disease in children, with a more severe onset and progression compared to adults. The prognosis of LN in children is worse than other glomerular diseases and has lifelong effects, although the etiology remains unclear. This article provides an overview of the current diagnosis and treatment status of LN in children, along with a brief description of the treatment for each type of LN based on the latest international guidelines. LN was diagnosed according to the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus. Renal biopsy pathology is an important diagnostic method at present. Treatment for proliferative and non-proliferative LN includes initial therapy and maintenance therapy, following recommendations from adult guidelines. Rational and proactive treatment is crucial for inducing disease remission, preventing relapse, and improving prognosis.
Key words： systemic lupus erythematosus; lupus nephritis; treatment; child
Chunlin GAO . Renal pathologic classification and treatment strategy in children with lupus nephritis[J]. Journal of Clinical Pediatrics, 2023 , 41(12) : 887 -894 . DOI: 10.12372/jcp.2023.23e0916
| [1] | Kamphuis S, Silverman ED. Prevalence and burden of pediatric-onset systemic lupus erythematosus[J]. Nat Rev Rheumatol, 2010, 6(9): 538-546. |
| [2] | Feldman CH, Broder A, Guan H, et al. Sex differences in health care utilization, end-stage renal disease, and mortality among medicaid beneficiaries with incident lupus nephritis[J]. Arthritis Rheumatol, 2018, 70(3): 417-426. |
| [3] | Fujikawa S, Okuni M. A nationwide surveillance study of rheumatic diseases among Japanese children[J]. Acta Paediatr Jpn, 1997, 39: 242-244. |
| [4] | Tsioni V, Andreoli L, Meini A, et al. The prevalence and incidence of systemic lupus erythematosus in children and adults: a population-based study in a mountain community in northern Italy[J]. Clin Exp Rheumatol, 2015, 33(5): 681-687. |
| [5] | Ambrose N, Morgan TA, Galloway J, et al. Differences in disease phenotype and severity in SLE across age groups[J]. Lupus, 2016, 25(14): 1542-1550. |
| [6] | Massias JS, Smith EMD, Al-Abadi E, et al. Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups[J]. Lupus, 2020, 29(5): 474-481. |
| [7] | Hiraki LT, Feldman CH, Liu J, et al. Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US medicaid beneficiary population[J]. Arthritis Rheum, 2012, 64: 2669-2676. |
| [8] | Massias JS, Smith EM, Al-Abadi E, et al. Clinical and laboratory phenotypes in juvenile-onset systemic lupus erythematosus across ethnicities in the UK[J]. Lupus, 2021, 30(4): 597-607. |
| [9] | Sassi RH, Hendler JV, Piccoli GF, et al. Age of onset influences on clinical and laboratory profile of patients with systemic lupus erythematosus[J]. Clin Rheumatol, 2017, 36(1): 89-95. |
| [10] | Wang SF, Chen YH, Chen DQ, et al. Mesangial proliferative lupus nephritis with podocytopathy: a special entity of lupus nephritis[J]. Lupus, 2018, 27(2): 303-311. |
| [11] | Oni L, Wright RD, Marks S, et al. Kidney outcomes for children with lupus nephritis[J]. Pediatr Nephrol, 2021, 36: 1377-1385. |
| [12] | Houssiau FA, Vasconcelos C, D'Cruz D, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial[J]. Arthritis Rheum, 2004, 50(12): 3934-3940. |
| [13] | Anders HJ, Saxena R, Zhao MH, et al. Lupus nephritis[J]. Nat Rev Dis Primers, 2020, 6(1): 7. |
| [14] | Lu R, Robertson JM, Bruner BF, et al. Multiple autoantibodies display association with lymphopenia, proteinuria, and cellular casts in a large, ethnically diverse SLE patient cohort[J]. Autoimmune Dis, 2012: 819634 |
| [15] | Santacruz JC, Mantilla MJ, Rueda I, et al. A practical perspective of the hematologic manifestations of systemic lupus erythematosus[J]. Cureus, 2022, 14(3): e22938. |
| [16] | Fayyaz A, Igoe A, Kurien BT, et al. Haematological manifestations of lupus[J]. Lupus Sci Med, 2015, 2(1): e000078. |
| [17] | Kocheril AP, Vettiyil GI, George AS, et al. Pediatric systemic lupus erythematosus with lupus anticoagulant hypoprothrombinemia syndrome-a case series with review of literature[J]. Lupus, 2021, 30(4): 641-648. |
| [18] | Suyama Y, Okada M, Rokutanda R, et al. Safety and efficacy of upfront graded administration of trimethoprim-sulfamethoxazole in systemic lupus erythematosus: a retrospective cohort study[J]. Mod Rheumatol, 2016, 26(4): 557-561. |
| [19] | Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis[J]. Ann Rheum Dis, 2020, 79(6): 713-723. |
| [20] | Kidney Disease: Improving Global Outcomes KDIGO Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular Diseases[J]. Kidney Int, 2021, 100(4S): S1-S276. |
| [21] | Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus[J]. Ann Rheum Dis, 2019, 78(9): 1151-1159. |
| [22] | 中华医学会儿科分会肾脏学组. 儿童狼疮性肾炎诊治循证指南(2016)[J]. 中华儿科杂志, 2018, 56(2): 88-94. |
| [23] | Wakiguchi H, Takei S, Kubota T, et al. Treatable renal disease in children with silent lupus nephritis detected by baseline biopsy: association with serum C3 levels[J]. Clin Rheumatol, 2017, 36(2): 433-437. |
| [24] | Narváez J, Ricse M, Gomà M, et al. The value of repeat biopsy in lupus nephritis flares[J]. Medicine (Baltimore), 2017, 96(24): e7099. |
| [25] | Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited[J]. Kidney Int, 2004, 65(2): 521-530. |
| [26] | Bajema IM, Wilhelmus S, Alpers CE, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices[J]. Kidney Int, 2018, 93(4): 789-796. |
| [27] | Hu W, Chen Y, Wang S, et al. Clinical-morphological features and outcomes of lupus podocytopathy[J]. Clin J Am Soc Nephrol, 2016, 11(4): 585-592. |
| [28] | Lee SJ, Silverman E, Bargman JM. The role of antimalarial agents in the treatment of SLE and lupus nephritis[J]. Nat Rev Nephrol, 2011, 7(12): 718-729. |
| [29] | Yusuf IH, Charbel Issa P, Ahn SJ. Hydroxychloroquine-induced retinal toxicity[J]. Front Pharmacol, 2023, 14: 1196783. |
| [30] | Anders HJ, Loutan J, Bruchfeld A, et al. The management of lupus nephritis as proposed by EULAR/ERA 2019 versus KDIGO 2021[J]. Nephrol Dial Transplant, 2023, 38(3): 551-561. |
| [31] | Houssiau FA, Vasconcelos C, D'Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide[J]. Ann Rheum Dis, 2010, 69(1): 61-64. |
| [32] | Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis[J]. J Am Soc Nephrol, 2009, 20: 1103-1112. |
| [33] | Yang TH, Wu TH, Chang YL, et al. Cyclosporine for the treatment of lupus nephritis in patients with systemic lupus erythematosus[J]. Clin Nephrol, 2018, 89: 277-285. |
| [34] | Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis[J]. N Engl J Med, 2005, 353: 2219-2228. |
| [35] | Chan TM, Tse KC, Tang CS, et al. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine[J]. Lupus, 2005, 14: 265-272. |
| [36] | Zhang M, Qi C, Zha Y, et al. Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial[J]. Clin Rheumatol, 2019, 38: 859-867. |
| [37] | Furie R, Rovin BH, Houssiau F, et al. Safety and efficacy of belimumab in patients with lupus nephritis open-label extension of BLISS-LN study[J]. Clin J Am Soc Nephrol, 2022, 17: 1620-1630. |
| [38] | Austin HA, 3rd, Illei GG, Braun MJ, et al. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy[J]. J Am Soc Nephrol, 2009, 20: 901-911. |
| [39] | Wasik H, Chadha V, Galbiati S, et al. Dialysis outcomes for children with lupus nephritis compared to children with other forms of nephritis: a retrospective cohort study[J]. Am J Kidney Dis, 2022, 79(5): 626-634. |
| [40] | Mai K, Singer P, Fahmy AE, et al. Kidney transplant outcomes in children and adolescents with systemic lupus erythematosus[J]. Pediatr Transplant, 2022, 26(1): e14178. |
| [41] | Gipson DS, Ferris ME, Dooley MA, et al. Renal transplantation in children with lupus nephritis[J]. Am J Kidney Dis, 2003, 41(2): 455-463. |
| [42] | Rangoonwala S, Marks SD. Kidney transplantation outcomes for children and young people with lupus nephritis[J]. Pediatr Transplant, 2022, 26(1): e14193. |
/
| 〈 |
|
〉 |
